A5075804863- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Esophageal Cancer Research and Treatment
- Urological Disorders and Treatments
- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Renal cell carcinoma treatment
- Molecular Biology Techniques and Applications
- Immune cells in cancer
- Glutathione Transferases and Polymorphisms
- Infectious Disease Case Reports and Treatments
- Cancer-related molecular mechanisms research
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Tea Polyphenols and Effects
- Prostate Cancer Treatment and Research
- Multiple and Secondary Primary Cancers
Lund University
2016-2025
Skåne University Hospital
2016-2025
Queen's University
2020-2022
Spanish National Cancer Research Centre
2020
Bipar
2013
Växjö Kommun
2012
Helsingborgs lasarett
2010
Abstract Purpose: Even though urothelial cancer is the fourth most common tumor type among males, progress in treatment has been scarce. A problem day-to-day clinical practice that precise assessment of individual tumors still fairly uncertain; consequently efforts have undertaken to complement evaluation with molecular biomarkers. An extension this approach would be base classification primarily on features. Here, we present a taxonomy for carcinoma based integrated genomics. Experimental...
Abstract Global mRNA expression analysis is efficient for phenotypic profiling of tumours, and has been used to define molecular subtypes almost every major tumour type. A key limitation that most tumours are communities both non‐tumour cells. This problem particularly pertinent advanced invasive which known induce changes responses in the surrounding tissue. To identify bladder cancer tumour‐cell phenotypes compare classification by phenotype with global gene analysis, we analysed 307...
Abstract In the present investigation, we sought to refine classification of urothelial carcinoma by combining information on gene expression, genomic, and mutation levels. For these purposes, performed expression analysis 144 carcinomas, whole genome array-CGH analyses FGFR3, PIK3CA, KRAS, HRAS, NRAS, TP53, CDKN2A, TSC1 in 103 cases. Hierarchical cluster identified two intrinsic molecular subtypes, MS1 MS2, which were validated defined same set genes three independent bladder cancer data...
Abstract The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed NMIBC ( n = 834). Transcriptomic identifies four classes (1, 2a, 2b and 3) reflecting tumor biology disease aggressiveness. Both transcriptome-based subtyping the level chromosomal instability provide independent prognostic value beyond established...
For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinical use to predict response neoadjuvant chemotherapy.To investigate how molecular subtypes impact pathological and survival in patients receiving preoperative cisplatin-based chemotherapy.Classification of a retrospective cohort 149 was performed by tumor transcriptomic profiling immunostaining. A treated with radical cystectomy alone public data sets were used comparison external validation.Complete the...
Similar to other malignancies, urothelial carcinoma (UC) is characterized by specific recurrent chromosomal aberrations and gene mutations. However, the interconnection between genomic alterations, how patterns of alterations adhere different molecular subgroups UC, less clear. We applied tiling resolution array CGH 146 cases UC identified a number regions harboring focal amplifications deletions. Several potential oncogenes were included in amplified regions, including known like E2F3,...
We recently defined molecular subtypes of urothelial carcinomas according to whole genome gene expression. Herein we describe pathologic characterization the using 20 genes and IHC 237 tumors. In addition differences in expression levels, show important stratification protein The selected included biological features central bladder cancer biology, eg, cell cycle activity, cellular architecture, cell-cell interactions, key receptor tyrosine kinases. that urobasal (Uro) A subtype shares with...
Abstract Global gene expression analysis has been a major tool for urothelial carcinoma subtype discovery. This approach revealed extensive complexity both in intrinsic features of the tumor cells and microenvironment. However, global cannot distinguish between signals originating from proper normal biopsy. Here, we use large cohort advanced carcinomas which data immunohistochemistry are available to create supervised mRNA centroid classifier. classifier identifies Lund taxonomy cell...
Urothelial carcinoma (UC) aggressiveness is determined by tumor inherent molecular characteristics, such as subtypes, well host reactions directed toward the tumor. Cell types responsible for host's response include tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). The aim of present investigation was to explore immunological in relation UC subtypes evaluate prognostic effect TIL TAM counts tissue sections from muscle-invasive (MI) tumors.Tissue microarrays with...
Abstract Molecular stratification of tumors by gene expression profiling has been applied to a large number human malignancies and holds great promise for personalized treatment. Comprehensive classification schemes urothelial carcinoma have proposed three separate groups but not previously evaluated simultaneously in independent data. Here we map the interrelations between molecular subtypes onto intrinsic structure rich dataset show that subtype within each scheme can be explained terms...
Background Urothelial carcinoma (UC) is characterized by frequent gene mutations of which activating in FGFR3 are the most frequent. Several downstream targets also mutated UC, e.g., PIK3CA, AKT1, and RAS. Most mutation studies UCs have been focused on single or a few genes at time performed small sample series. This has limited possibility to investigate co-occurrence mutations. Methodology/Principal Findings We analyses 16 genes, FGFR3, PIK3R1 PTEN, KRAS, HRAS, NRAS, BRAF, ARAF, RAF1,...
Molecular changes occurring during invasion and clinical progression of cancer are difficult to study longitudinally in patient‐derived material. A unique feature urothelial bladder (UBC) is that patients frequently develop multiple nonmuscle invasive tumors, some which may eventually progress invade the muscle wall. Here, we use a cohort 73 experienced total 357 UBC diagnoses stability or change detected molecular alterations progression. The tumors were subtyped by gene expression...
Molecular stratification of bladder cancer has revealed gene signatures differentially expressed across tumor subtypes. While these provide important insights into subtype biology, the transcriptional regulation that governs is not well characterized. In this study, we use publically available ChIP-Seq data on regulatory factor binding in order to link transcription factors defining molecular subtypes urothelial carcinoma. We identify PPARG and STAT3, as ADIRF, a novel regulator fatty acid...
We assessed DNA methylation and copy number status of 27,000 CpGs in 149 urothelial carcinomas integrated the findings with gene expression mutation data. Methylation was associated for 1,332 CpGs, which 26% showed positive correlation expression, i.e., high levels. These positively correlated were part specific transcription factor binding sites, such as sites MYC CREBP1, or located bodies. Furthermore, we found genes gains, low levels, revealing an association between This phenomenon...
// Pontus Eriksson 1 , Gottfrid Sjödahl 2 Gunilla Chebil 3 Fredrik Liedberg and Mattias Höglund Division of Oncology Pathology, Department Clinical Sciences, Lund University, Lund, Sweden Urological Research, Translational Medicine, Skåne University Hospital, Malmö, Unilabs, Helsingborg Helsingborg, Correspondence to: Höglund, email: mattias.hoglund@med.lu.se Keywords: HER2, EGFR, amplification, urothelial carcinoma, molecular subtype Received: November 15, 2016 Accepted: March 08, 2017...